Alzheimer’s drug that showed significant difference in early trials approved for use in Canada
May 04, 2026
May 04, 2026
A drug that may slow progression of dementia in some patients has been approved for use in Canada, the manufacturer announced.
Donanemab is the “first and only amyloid plaque-targeting therapy with evidence supporting stopping treatment once amyloid plaques are cleared,” Eli Lilly Canada Inc. said in a statement announcing the approval Monday.
Clumps of the protein amyloid may lead to cognitive and memory problems typically linked to Alzheimer’s, the drugmaker said. Donanemab helps the body remove this buildup.
The drug was already approved by the United States and European Union and sold under the name Kisunla.
The monthly treatment is now available for some Canadians with early symptomatic Alzheimer’s disease, Eli Lilly Canada said.
‘This drug is not a cure’
Early research on the drug was promising for some, with nearly half of participants showing no clinical progression of dementia in the first year of use, the Canadian organization Alzheimer Society wrote in a previous update on the approval process.
Mainstream NewsBed Bug Infestation Forces Closure of Fort Simpson Schools
Two schools in Fort Simpson, N.W.T., will close starting Monday due to a bed bug infestation, with no confirmed reopening date.
Mainstream NewsThe Complex History of Bible Translations in Greenland and Labrador
Early Christian missionaries in Greenland and Labrador relied on Inuit converts to translate the Bible, revealing a complex interplay of cultural exchange and religious adaptation.
Mainstream NewsInuit-Led Pirutsiagutiit Program Replaces Child First Initiative
Federal government transfers $575M in child health and social support funding to Inuit organizations, ending uncertainty over previous program.
Mainstream NewsWhitehorse Students Engage With Canadian Astronauts Aboard the ISS
Students from Whitehorse schools connected with Canadian astronauts Jenni Gibbons and Joshua Kutryk, gaining insights into space exploration and inspiring future careers in science.